Havel & Partners has successfully represented the Roche Group before the Czech Arbitration Court in a domain dispute.
According to Havel & Partners, “when registering a new medicinal product, Roche discovered that the required Czech domain name had already been registered by someone else. That registration took place on the day Roche publicly announced the name of the new medicinal product. This was therefore an example of so-called cybersquatting, which is the deliberate registration of a domain name at the expense of another brand. The domain name holder demanded several million Czech crowns from Roche for the domain name transfer.”
“Based on the award of the Arbitration Court attached to the Economic Chamber of the Czech Republic and Agricultural Chamber of the Czech Republic in ADR proceedings, the domain name was subsequently transferred to Roche for no consideration,” the firm added.
Roche is a Basel-headquartered pharmaceuticals and diagnostics company focusing on the production of medicinal products in the areas of oncology, immunology, infectious diseases, ophthalmology, and central nervous system diseases. The Roche Group operates in more than 100 countries worldwide.
The Havel & Partners team included Partner Ivan Rames and Associates Tomas Chmelka and Matej Kurtin.